Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815

Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

P F Troke, R J Andrews, K W Brammer, M S Marriott, K Richardson
PMCID: PMC180335  PMID: 3002246

Abstract

UK-49,858 (fluconazole), a new, orally absorbed bis-triazole derivative, has been evaluated against systemic infections with Candida albicans in normal and immunosuppressed mice and against an intestinal infection with C. albicans in immunosuppressed mice. Orally administered ketoconazole was used as a comparison agent throughout, and orally administered amphotericin B was included for comparative in the experimental intestinal infection. In a 10-day dosage regimen, UK-49,858 was far more active than ketoconazole against systemic infections with C. albicans in normal and immunosuppressed mice. In normal mice, extension of UK-49,858 dosing to 30 days resulted in prolongation of survival to over 90 days, and up to 60% of treated animals had no detectable C. albicans in their kidneys. In addition, over 90% of mice with intestinal candidiasis had culture-negative feces after a 3-day treatment with UK-49,858, but only 62 and 23% of mice gave this response after amphotericin B and ketoconazole therapy, respectively. These data suggest that UK-49,858 may be of value in the treatment of systemic and gastrointestinal infections due to C. albicans in humans.

Full text

PDF
815

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borelli D., Bran J. L., Fuentes J., Legendre R., Leiderman E., Levine H. B., Restrepo A., Stevens D. A. Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J. 1979 Sep;55(647):657–661. doi: 10.1136/pgmj.55.647.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bullock W. E., Deepe G. S., Jr Medical mycology in crisis. J Lab Clin Med. 1983 Nov;102(5):685–693. [PubMed] [Google Scholar]
  3. Fraser D. W., Ward J. I., Ajello L., Plikaytis B. D. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979 Oct 12;242(15):1631–1635. [PubMed] [Google Scholar]
  4. Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs. 1983 Jan;25(1):41–62. doi: 10.2165/00003495-198325010-00003. [DOI] [PubMed] [Google Scholar]
  5. Helstrom P. B., Balish E. Effect of oral tetracycline, the microbial flora, and the athymic state on gastrointestinal colonization and infection of BALB/c mice with Candida albicans. Infect Immun. 1979 Mar;23(3):764–774. doi: 10.1128/iai.23.3.764-774.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Marsh P. K., Tally F. P., Kellum J., Callow A., Gorbach S. L. Candida infections in surgical patients. Ann Surg. 1983 Jul;198(1):42–47. doi: 10.1097/00000658-198307000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meunier-Carpentier F. Treatment of mycoses in cancer patients. Am J Med. 1983 Jan 24;74(1B):74–79. doi: 10.1016/0002-9343(83)90518-1. [DOI] [PubMed] [Google Scholar]
  10. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  12. Schwartz R. S., Mackintosh F. R., Schrier S. L., Greenberg P. L. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer. 1984 Feb 1;53(3):411–419. doi: 10.1002/1097-0142(19840201)53:3<411::aid-cncr2820530308>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  13. Stamm A. M., Dismukes W. E. Current therapy of pulmonary and disseminated fungal diseases. Chest. 1983 Jun;83(6):911–917. doi: 10.1378/chest.83.6.911. [DOI] [PubMed] [Google Scholar]
  14. Turner J. R., Butler T. F., Johnson M. E., Gordee R. S. Colonization of the intestinal tract of conventional mice with Candida albicans and treatment with antifungal agents. Antimicrob Agents Chemother. 1976 May;9(5):787–792. doi: 10.1128/aac.9.5.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Umenai T., Konno S., Ishida N. Systemic candidiasis from Candida albicans colonizing the gastrointestinal tract of mice. Experientia. 1979 Oct 15;35(10):1331–1332. doi: 10.1007/BF01963990. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES